Effect of Combination Therapy Including Protease Inhibitors on Mortality among Children and Adolescents Infected with HIV-1
Top Cited Papers
Open Access
- 22 November 2001
- journal article
- clinical trial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 345 (21) , 1522-1528
- https://doi.org/10.1056/nejmoa011157
Abstract
Combination therapy including protease inhibitors has been shown to be effective in treating adults infected with human immunodeficiency virus type 1 (HIV-1), but there are only limited data regarding the treatment of children and adolescents. A cohort of 1028 HIV-1–infected children and adolescents, from birth through 20 years of age, who were enrolled in research clinics in the United States before 1996 was followed prospectively through 1999. We used proportional-hazards regression models to estimate the effect on mortality of combination therapy including protease inhibitors. Seven percent of the subjects were receiving combination therapy including protease inhibitors in 1996; by 1999, 73 percent were receiving such therapy. In univariate analyses, a higher base-line percentage of lymphocytes that were CD4-positive, a higher weight for age, a higher height for age, black race, Hispanic ethnic background, younger age, and perinatally acquired infection were associated with a longer median time to the initiation of this type of therapy (P<0.001). After adjustment for covariates, the differences among racial and ethnic groups in the time to initiation were not statistically significant. Mortality declined from 5.3 percent in 1996 to 2.1 percent in 1997, 0.9 percent in 1998, and 0.7 percent in 1999 (P for trend <0.001). There were reductions in mortality in all subgroups defined according to age, sex, percentage of CD4+ lymphocytes, educational level of the parent or guardian, and race or ethnic background. In adjusted analyses, the initiation of combination therapy including protease inhibitors was independently associated with reduced mortality (hazard ratio for death, 0.33; 95 percent confidence interval, 0.19 to 0.58; P<0.001). The use of combination therapy including protease inhibitors has markedly reduced mortality among children and adolescents infected with HIV-1.Keywords
This publication has 27 references indexed in Scilit:
- Impact of Protease Inhibitor-Containing Combination Antiretroviral Therapies on Height and Weight Growth in HIV-Infected ChildrenPediatrics, 2001
- Lipodystrophy in HIV-Infected Children Is Associated With High Viral Load and Low CD4+-Lymphocyte Count and CD4+-Lymphocyte Percentage at Baseline and Use of Protease Inhibitors and StavudineJAIDS Journal of Acquired Immune Deficiency Syndromes, 2001
- Combination Nucleoside Analog Reverse Transcriptase Inhibitor(s) Plus Nevirapine, Nelfinavir, or Ritonavir in Stable Antiretroviral Therapy-Experienced HIV-Infected Children: Week 24 Results of a Randomized Controlled Trial - PACTG 377AIDS Research and Human Retroviruses, 2000
- Factors Affecting Adherence to Antiretroviral TherapyClinical Infectious Diseases, 2000
- Predictors of Self-Reported Adherence and Plasma HIV Concentrations in Patients on Multidrug Antiretroviral RegimensJAIDS Journal of Acquired Immune Deficiency Syndromes, 2000
- Use of observational databases to evaluate the effectiveness of antiretroviral therapy for HIV infection: comparison of cohort studies with randomized trialsAIDS, 1999
- Serum HIV-1 p24 antibody, HIV-1 RNA copy number and CD4 lymphocyte percentage are independently associated with risk of mortality in HIV-1-infected childrenAIDS, 1999
- A Phase I/II Study of the Protease Inhibitor Indinavir in Children With HIV InfectionPublished by American Academy of Pediatrics (AAP) ,1998
- The relation between hospital experience and mortality for patients with AIDSPublished by American Medical Association (AMA) ,1992
- Comparison of baseline and repeated measure covariate techniques in the Framingham heart studyStatistics in Medicine, 1988